DOCSLIB.ORG

Evaluation of Leakage from Fume Hoods Using Tracer Gas, Tracer Nanoparticles and Nanopowder Handling Test Methodologies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Leakage from Fume Hoods Using Tracer Gas, Tracer Nanoparticles and Nanopowder Handling Test Methodologies HHS Public Access Author manuscript Author Manuscript Author ManuscriptJ Occup Author Manuscript Environ Hyg. Author Author Manuscript manuscript; available in PMC 2015 August 17. Published in final edited form as: J Occup Environ Hyg. 2014 ; 11(10): D164–D173. doi:10.1080/15459624.2014.933959. EVALUATION OF LEAKAGE FROM FUME HOODS USING TRACER GAS, TRACER NANOPARTICLES AND NANOPOWDER HANDLING TEST METHODOLOGIES Kevin H. Dunn1,*, Candace Su-Jung Tsai2, Susan R. Woskie3, James S. Bennett1, Alberto Garcia1, and Michael J. Ellenbecker3 1Engineering and Physical Hazards Branch, Division of Applied Research and Technology, National Institute for Occupational Safety and Health, Cincinnati, OH 2School of Health Sciences, Purdue University, West Lafayette, IN 3Department of Work Environment, College of Health Sciences, University of Massachusetts Lowell, Lowell, MA Abstract The most commonly reported control used to minimize workplace exposures to nanomaterials is the chemical fume hood. Studies have shown, however, that significant releases of nanoparticles can occur when materials are handled inside fume hoods. This study evaluated the performance of a new commercially available nano fume hood using three different test protocols. Tracer gas, tracer nanoparticle, and nanopowder handling protocols were used to evaluate the hood. A static test procedure using tracer gas (sulfur hexafluoride) and nanoparticles as well as an active test using an operator handling nanoalumina were conducted. A commercially available particle generator was used to produce sodium chloride tracer nanoparticles. Containment effectiveness was evaluated by sampling both in the breathing zone (BZ) of a mannequin and operator as well as across the hood opening. These containment tests were conducted across a range of hood face velocities (60, 80, and 100 feet/minute) and with the room ventilation system turned off and on. For the tracer gas and tracer nanoparticle tests, leakage was much more prominent on the left side of the hood (closest to the room supply air diffuser) although some leakage was noted on the right side and in the BZ sample locations. During the tracer gas and tracer nanoparticle tests, leakage was primarily noted when the room air conditioner was on for both the low and medium hood exhaust air flows. When the room air conditioner was turned off, the static tracer gas tests showed good containment across most test conditions. The tracer gas and nanoparticle test results were well correlated showing hood leakage under the same conditions and at the same sample locations. The impact of a room air conditioner was demonstrated with containment being adversely impacted during the use of room air ventilation. The tracer nanoparticle approach is a simple method requiring minimal setup and instrumentation. However, the method requires the reduction in background concentrations to allow for increased sensitivity. *indicates the corresponding author with, [email protected]. Disclaimer: Mention of a specific product or company does not constitute endorsement by the Centers for Disease Control and Prevention. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Dunn et al. Page 2 Author ManuscriptKeywords Author Manuscript Author Manuscript Author Manuscript nanoparticle; fume hood; containment; tracer gas INTRODUCTION Occupational health risks associated with manufacturing and the use of nanomaterials are not yet clearly understood. However, initial toxicological data indicate that there is reason for caution. Pulmonary inflammation has been observed in animals exposed to titanium (1-3) dioxide (TiO2) and carbon. Other studies have shown that nanoparticles can translocate to the circulatory system and to the brain and cause oxidative stress.(4, 5) Perhaps the most troubling finding is that carbon nanotubes can elicit asbestos-like responses in mice.(6, 7) In light of these results, it is important for producers and users of engineered nanomaterials to reduce employee exposure and manage risks appropriately. A survey was conducted of producers and users of engineered carbonaceous nanomaterials (ECNs) in the U.S. at a research and development or pilot scale plant with plans to scale up within 5 years.(8) All participating companies reported using some sort of engineering control to reduce worker exposure to ECN. The most commonly reported control used to minimize workplace exposures to ECN was the chemical fume hood. Recent research has shown that the fume hood may allow releases of nanomaterials during their handling and manipulation.(9) This research evaluated exposures related to the handling (i.e., scooping and pouring) of powder nanoalumina and nanosilver in a constant air volume (CAV) hood, a bypass hood, and a variable air volume (VAV) hood. The study showed that the conventional fume hood in which face velocity varies inversely with sash height allowed the release of significant amounts of nanoparticles during pouring and transferring activities involving nanoalumina. New lower flow hoods adapted from pharmaceutical powder handling enclosures are being marketed and used for the manipulation of nanomaterials. The use of lower flows may reduce the impact of turbulence and the body wake on the potential for fume hood leakage. However, there is little information on their performance in the scientific literature. A common method used to evaluate performance of fume hoods is the quantitative tracer gas test. These tests are sometimes conducted with a mannequin in front of the hood to simulate the effect of the user on the air patterns surrounding the face of the hood. For these tests, a tracer gas (typically sulfur hexafluoride, SF6) is released inside the hood using a dispersion device. The performance of the hood is evaluated by measuring the tracer gas concentration at the breathing zone (BZ) of the mannequin or at the hood opening. Tseng et al. evaluated the results of British, European and American protocols for tracer gas fume hood testing using a traditional laboratory fume hood. This testing showed that airflow patterns and the performance of the hood are integrally related.(10) The choice of source position, hood design and presence of a mannequin are important to a careful evaluation of the fume hood. The American Society of Heating, Refrigerating and Air-conditioning Engineers (ASHRAE) standard evaluates fume hood performance based on the traditional industrial hygiene precept of evaluating operator breathing zone exposure.(11) Tseng et al. J Occup Environ Hyg. Author manuscript; available in PMC 2015 August 17. Dunn et al. Page 3 found, however, that this method failed to detect serious leakages which may not be Author Manuscript Author Manuscript Author Manuscript Author Manuscript acceptable for hazardous materials. The British standard suffered from a measurement method which averages the spatial variability and dampened the effect of local leaks by combining sample flows from all locations across the hood face. New test methods need to be developed and evaluated. Most laboratory fume hood test protocols used today are based on utilizing SF6. SF6, however, has been identified as a strong greenhouse gas with a global warming potential 23,900 times greater than carbon (12) dioxide. The state of California has prohibited the sale and use of SF6 for a broad range of applications and allowed the use for one-time testing of fume hoods “for the purpose of reducing laboratory fume hood face velocity when the hood is unattended and realizing the associated energy savings”.(13) ASHRAE Technical Committee TC 9.10, Laboratory Ventilation, has recommended research to investigate potential replacement tracers critical for verification of laboratory fume hood devices. This study evaluated the performance of a new nano fume hood across three different hood exhaust air flows using three different test protocols. For the testing, tracer gas, tracer nanoparticle and nanopowder handling protocols were used to evaluate the hood. A static test procedure using tracer gas and nanoparticles and an active test using an operator handling nanoalumina were conducted. Samplers were placed in the operator breathing zone as well as at the left and right corner of the hood to assess leakage from the hood at areas known to have high turbulence. These containment tests were conducted with the room ventilation system turned off and again with the system on. The results of the three test methods are compared across the range of test conditions. METHODS Description of Hood and Laboratory Space The nano fume hood evaluated has interior dimensions of 20.3 inches (51.6 cm) (height) × 32 in (81.2 cm) (width) with an internal working depth of 30 in (76.3 cm) and a face opening of 9.5 in (24.1 cm) (height) × 32 in (81.2 cm) (width). The hood is constructed out of cast acrylic with a phenolic resin base. The enclosure includes a variety of features to reduce turbulence and improve containment performance. Molded airfoils are included at both sideposts, at the base of the hood inlet, and along the bottom of the hood sash. This enclosure was based on a pharmaceutical balance enclosure designed to protect workers during the handling of active pharmaceutical ingredients and to provide a low turbulence environment for weighing of materials on microbalances. This hood was located in a laboratory which was 10.5 feet (3.2 m) wide by 21 ft (6.7 m) deep with a ceiling height of 9.4 ft (2.9 m). A 2 ft (61 cm) × 2 ft (61 cm) ceiling-mounted supply air diffuser was located at the center of the room and slightly to the left of the hood face (Figures 1a and b). Ventilation measurements Airflow measurements were taken to characterize the inlet air flow profile at the face of the nano fume hood. A traverse of the hood face with a hot wire anemometer was conducted to evaluate the spatial and temporal variation in air velocities entering the hood. The air J Occup Environ Hyg.
Load more

Recommended publications
  • Sulfur Hexafluoride Hazard Summary Identification
    Common Name: SULFUR HEXAFLUORIDE CAS Number: 2551-62-4 RTK Substance number: 1760 DOT Number: UN 1080 Date: April 2002 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY * Sulfur Hexafluoride can affect you when breathed in. * If you think you are experiencing any work-related health * Sulfur Hexafluoride can irritate the skin causing a rash or problems, see a doctor trained to recognize occupational burning feeling on contact. Direct skin contact can cause diseases. Take this Fact Sheet with you. frostbite. * Exposure to hazardous substances should be routinely * Sulfur Hexafluoride may cause severe eye burns leading evaluated. This may include collecting personal and area to permanent damage. air samples. You can obtain copies of sampling results * Breathing Sulfur Hexafluoride can irritate the nose and from your employer. You have a legal right to this throat. information under OSHA 1910.1020. * Breathing Sulfur Hexafluoride may irritate the lungs causing coughing and/or shortness of breath. Higher WORKPLACE EXPOSURE LIMITS exposures can cause a build-up of fluid in the lungs OSHA: The legal airborne permissible exposure limit (pulmonary edema), a medical emergency, with severe (PEL) is 1,000 ppm averaged over an 8-hour shortness of breath. workshift. * High exposure can cause headache, confusion, dizziness, suffocation, fainting, seizures and coma. NIOSH: The recommended airborne exposure limit is * Sulfur Hexafluoride may damage the liver and kidneys. 1,000 ppm averaged over a 10-hour workshift. * Repeated high exposure can cause deposits of Fluorides in the bones and teeth, a condition called “Fluorosis.” This ACGIH: The recommended airborne exposure limit is may cause pain, disability and mottling of the teeth.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • Selection and Evaluation of a Silver Nanoparticle Imaging Agent for Dual-Energy Mammography
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2014 Selection and Evaluation of a Silver Nanoparticle Imaging Agent for Dual-Energy Mammography Roshan Anuradha Karunamuni University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biomedical Commons Recommended Citation Karunamuni, Roshan Anuradha, "Selection and Evaluation of a Silver Nanoparticle Imaging Agent for Dual- Energy Mammography" (2014). Publicly Accessible Penn Dissertations. 1326. https://repository.upenn.edu/edissertations/1326 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1326 For more information, please contact [email protected]. Selection and Evaluation of a Silver Nanoparticle Imaging Agent for Dual-Energy Mammography Abstract Over the past decade, contrast-enhanced (CE) dual-energy (DE) x-ray breast imaging has emerged as an exciting, new modality to provide high quality anatomic and functional information of the breast. The combination of these data in a single imaging procedure represents a powerful tool for the detection and diagnosis of breast cancer. The most widely used implementation of CEDE imaging is k-edge imaging, whereby two x-ray spectra are placed on either side of the k-edge of the contrast material. Currently, CEDE imaging is performed with iodinated contrast agents. The lower energies used in clinical DE breast imaging systems compared to imaging systems for other organs suggest that an alternative material may be better suited. We developed an analytical model to compare the contrast of various elements in the periodic table. The model predicts that materials with atomic numbers from 42 to 52 should provide the best contrast in DE breast imaging while still providing high-quality anatomical images.
    [Show full text]
  • Making Better Use of Clinical Trials
    Making better use of clinical trials Computational decision support methods for evidence-based drug benefit-risk assessment ZOL OFT PAXIL PLACEBO 75 PROZAC 20mg Gert van Valkenhoef Making better use of clinical trials Computational decision support methods for evidence-based drug benefit-risk assessment Proefschrift ter verkrijging van het doctoraat in de Medische Wetenschappen aan de Rijksuniversiteit Groningen op gezag van de Rector Magnificus, dr. E. Sterken, in het openbaar te verdedigen op woensdag 19 december 2012 om 14:30 uur door Gerardus Hendrikus Margondus van Valkenhoef geboren op 25 juli 1985 te Amersfoort Promotores: Prof. dr. J.L. Hillege Prof. dr. E.O. de Brock Copromotor: Dr. T.P. Tervonen Beoordelingscommissie: Prof. dr. A.E. Ades Prof. dr. E.R. van den Heuvel Prof. dr. M.J. Postma ISBN 978-90-367-5884-0 (PDF e-book) iii This thesis was produced in the context of the Escher Project (T6-202), a project of the Dutch Top Institute Pharma. The Escher Project brings together university and pharmaceutical partners with the aim of energizing pharmaceutical R & D by iden- tifying, evaluating, and removing regulatory and methodological barriers in order to bring efficacious and safe medicines to patients in an efficient and timely fashion. The project focuses on delivering evidence and credibility for regulatory reform and policy recommendations. The work was performed at the Faculty of Economics and Business, University of Groningen (2009 – 2010), at the Department of Epidemiology, University Medical Center Groningen (2010-2012), and during a series of research visits to the Depart- ment of Community Based Medicine, University of Bristol.
    [Show full text]
  • Gasket Chemical Services Guide
    Gasket Chemical Services Guide Revision: GSG-100 6490 Rev.(AA) • The information contained herein is general in nature and recommendations are valid only for Victaulic compounds. • Gasket compatibility is dependent upon a number of factors. Suitability for a particular application must be determined by a competent individual familiar with system-specific conditions. • Victaulic offers no warranties, expressed or implied, of a product in any application. Contact your Victaulic sales representative to ensure the best gasket is selected for a particular service. Failure to follow these instructions could cause system failure, resulting in serious personal injury and property damage. Rating Code Key 1 Most Applications 2 Limited Applications 3 Restricted Applications (Nitrile) (EPDM) Grade E (Silicone) GRADE L GRADE T GRADE A GRADE V GRADE O GRADE M (Neoprene) GRADE M2 --- Insufficient Data (White Nitrile) GRADE CHP-2 (Epichlorohydrin) (Fluoroelastomer) (Fluoroelastomer) (Halogenated Butyl) (Hydrogenated Nitrile) Chemical GRADE ST / H Abietic Acid --- --- --- --- --- --- --- --- --- --- Acetaldehyde 2 3 3 3 3 --- --- 2 --- 3 Acetamide 1 1 1 1 2 --- --- 2 --- 3 Acetanilide 1 3 3 3 1 --- --- 2 --- 3 Acetic Acid, 30% 1 2 2 2 1 --- 2 1 2 3 Acetic Acid, 5% 1 2 2 2 1 --- 2 1 1 3 Acetic Acid, Glacial 1 3 3 3 3 --- 3 2 3 3 Acetic Acid, Hot, High Pressure 3 3 3 3 3 --- 3 3 3 3 Acetic Anhydride 2 3 3 3 2 --- 3 3 --- 3 Acetoacetic Acid 1 3 3 3 1 --- --- 2 --- 3 Acetone 1 3 3 3 3 --- 3 3 3 3 Acetone Cyanohydrin 1 3 3 3 1 --- --- 2 --- 3 Acetonitrile 1 3 3 3 1 --- --- --- --- 3 Acetophenetidine 3 2 2 2 3 --- --- --- --- 1 Acetophenone 1 3 3 3 3 --- 3 3 --- 3 Acetotoluidide 3 2 2 2 3 --- --- --- --- 1 Acetyl Acetone 1 3 3 3 3 --- 3 3 --- 3 The data and recommendations presented are based upon the best information available resulting from a combination of Victaulic's field experience, laboratory testing and recommendations supplied by prime producers of basic copolymer materials.
    [Show full text]
  • AP0599 Nanoparticle Decoration of Carbon Nanotubes by Sputtering
    Hiden Reference: AP0599 Hiden Product: EQP 1000 Nanoparticle decoration of carbon nanotubes by sputtering Nanoparticle-decorated carbon nanotubes (CNTs) are effective chemical and biological sensors, surfaces for heterogeneous catalysis, photovoltaics, and conformal thermal interface materials for electronics. The particle morphology on the CNT sidewalls strongly affects the properties and performance of metal-nanotube hybrids for such applications. Often nanoparticles are deposited by electrochemical methods, which generally require time consuming treatments with strong acid for surface defect production, which can result in a compromise of the intrinsic mechanical or transport properties of the CNTs, inhibiting their multi-functionality. We have examined physical vapor deposition techniques as scalable alternatives to electrochemical treatment for in situ growth of metal nanoparticles on the sidewalls of multi-wall carbon nanotubes (MWCNTs). Vapor phase growth of gold, nickel and titanium metal nanoparticles on multi-wall carbon nanotube (MWCNT) bucky paper was investigated. The size and distribution of nanoparticles was dependent on the intrinsic binding energy of the elemental metals, where metals with larger cohesive energies exhibited a higher nanoparticle density and smaller particle diameters. Particle diameters for any metal could be altered to mimic that of metals with different binding energies by in situ modification of the MWCNT surfaces by energetic metal ions (characterized with a Hiden EQP 1000 as shown in Figure 1) during their growth, where removal of a carbon atom from a MWCNT surface requires incident ions kinetic energies > 5-7 eV. Control of the ariel density, diameter and morphology of metal nanoparticles grown on as-received and annealed multi- walled carbon nanotube sidewalls by sputtering was demonstrated for gold, nickel and titanium.
    [Show full text]
  • BGA244 Binary Gas Analyzer User Manual
    BGA244 Binary Gas Analyzer User Manual Revision 1.10 Certification Stanford Research Systems certifies that this product met its published specification at the time of shipment. Warranty This Stanford Research Systems product is warranted against defects in materials and workmanship for a period of one (1) year from the date of shipment. Service For warranty service or repair, this product must be returned to a Stanford Research Systems authorized service facility. Contact Stanford Research Systems or an authorized representative for a RMA (Return Material Authorization) Number before returning this product for repair. These are available at www.thinksrs.com under Support, Repair/Calibration. All users returning a BGA244 back to the factory for repair and/or service must submit a correctly completed “Declaration of Contamination of Equipment” form, available as part of the RMA process. The SRS personnel carrying out repair and service of the BGA244 must be informed of the condition of the components prior to any work being performed. Warning All returns to SRS must be free of harmful, corrosive, radioactive or toxic materials. Dedication In memory of Jim Williams, 1948 - 2011: Legendary Author and Analog Design Guru Information in this document is subject to change without notice. Copyright © Stanford Research Systems, Inc., 2016-2018. All rights reserved. Stanford Research Systems, Inc. 1290-C Reamwood Avenue Sunnyvale, California 94089 Phone: (408) 744-9040 Fax: (408) 744-9049 Email: [email protected] www.thinksrs.com Printed in the
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • In-Vitro Cell Exposure Studies for the Assessment of Nanoparticle Toxicity in the Lung—A Dialog Between Aerosol Science and Biology$
    Journal of Aerosol Science 42 (2011) 668–692 Contents lists available at ScienceDirect Journal of Aerosol Science journal homepage: www.elsevier.com/locate/jaerosci In-vitro cell exposure studies for the assessment of nanoparticle toxicity in the lung—A dialog between aerosol science and biology$ Hanns-Rudolf Paur a, Flemming R. Cassee b, Justin Teeguarden c, Heinz Fissan d, Silvia Diabate e, Michaela Aufderheide f, Wolfgang G. Kreyling g, Otto Hanninen¨ h, Gerhard Kasper i, Michael Riediker j, Barbara Rothen-Rutishauser k, Otmar Schmid g,n a Institut fur¨ Technische Chemie (ITC-TAB), Karlsruher Institut fur¨ Technologie, Campus Nord, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany b Center for Environmental Health, National Institute for Public Health and the Environment, P.O. Box 1, 3720 MA Bilthoven, The Netherlands c Pacific Northwest National Laboratory, Fundamental and Computational Science Directorate, 902 Battelle Boulevard, Richland, WA 99352, USA d Institute of Energy and Environmental Technologies (IUTA), Duisburg, Germany e Institut fur¨ Toxikologie und Genetik, Karlsruher Institut fur¨ Technologie, Campus Nord, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany f Cultex Laboratories, Feodor-Lynen-Straße 21, 30625 Hannover, Germany g Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum Munchen,¨ Ingolstadter¨ Landstrasse 1, 85764 Neuherberg, Germany h THL National Institute for Health and Welfare, PO Box 95, 70701 Kuopio, Finland i Institut fur¨
    [Show full text]
  • Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded
    Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded edited by John A. Adamovics Cytogen Corporation Princeton, New Jersey Marcel Dekker, Inc. New York-Basel «Hong Kong Preface ISBN: 0-8247-9776-0 The first edition of Chromatographic Analysis of Pharmaceuticals was The publisher offers discounts on this book when ordered in bulk quanti­ published in 1990. The past years have allowed me to evaluate leads that I ties. For more information, write to Special Sales/Professional Marketing uncovered during the researching of the first edition, such as the first pub­ at the address below. lished example of the application of chromatography to pharmaceutical analysis of medicinal plants. This and other examples are found in a rela­ This book is printed on acid-free paper. tively rare book, Uber Kapillaranalyse und ihre Anwendung in Pharmazeu- tichen Laboratorium (Leipzig, 1992), by H. Platz. Capillary analysis, the Copyright © 1997 by Marcel Dekker, Inc. All Rights Reserved. chromatographic technique used, was developed by Friedlieb Runge in the mid-1850s and was later refined by Friedrich Goppelsroeder. The principle Neither this book nor any part may be reproduced or transmitted in any of the analysis was that substances were absorbed on filter paper directly form or by any means, electronic or mechanical, including photocopying, from the solutions in which they were dissolved; they then migrated to microfilming, and recording, or by any information storage and retrieval different points on the filter paper. Capillary analysis differed from paper system, without permission in writing from the publisher. chromatography in that no developing solvent was used. We find that, from these humble beginnings 150 years ago, the direct descendant of this Marcel Dekker, Inc.
    [Show full text]
  • Supplementary Information
    Electronic Supplementary Material (ESI) for Chemical Science This journal is © The Royal Society of Chemistry 2013 Supplementary Information Characterization of Silver Ion Dissolution from Silver Nanoparticles using Fluorous-phase Ion-selective Electrodes and Assessment of Resultant Toxicity to Shewanella oneidensis Melissa A. Maurer-Jones,† Maral P.S. Mousavi,† Li D. Chen, Philippe Bühlmann* and Christy L. Haynes* Department of Chemistry, University of Minnesota, 207 Pleasant St SE, Minneapolis, MN 55455, United States of America Fax: 612-626-7541; Tel: 612-626-1096; Email: [email protected], [email protected] † These authors contributed equally to this work. Electronic Supplementary Material (ESI) for Chemical Science This journal is © The Royal Society of Chemistry 2013 Experimental Methods Nanoparticle Synthesis and Characterization Citrate-capped Ag NPs were synthesized freshly for every experiment following a procedure detailed by Hackley and coworkers.1 Prior to synthesis, glassware was cleaned with aqua regia (3:1 HCl:HNO3) and rinsed three times with deionized purified water (18MΩ∙cm specific resistance, EMD Millipore, Burlington, MA, USA). For the synthesis, 50 mL deionized water was brought to a boil and then 365 μL of 34 mM trisodium citrate dihydrate (Sigma Aldrich, St. Louis, MO, USA) and 211 μL AgNO3 (Sigma Aldrich) were added, followed by drop-wise addition of freshly prepared 250 μL NaBH4 (Sigma Aldrich). Upon addition of NaBH4, the solution immediately turned yellow, and the mixture was allowed to boil for 15 min before removing the nanoparticles from heat and allowing them to come to room temperature. Nanoparticles were purified with regenerated cellulose (MWCO 50,000) centrifugal filter units (EMD Millipore) where 15 mL of the nanoparticle suspension were centrifuged at 1500 g for 4 min and then resuspended in deionized water, with the centrifuge/resuspension steps repeated in triplicate.
    [Show full text]
  • A Specialty Pharma Growth Story Disclaimer
    Rovi A Specialty Pharma Growth Story Disclaimer This document has been prepared by Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”), solely for its use during the attached presentation. The information and each of the opinions and statements contained in this document have not been verified by independent experts and, therefore, no guarantee is provided of the impartiality, accuracy, completeness or precision of the information or opinions and statements contained in this presentation. The Company and its advisors do not assume responsibility for any damage or losses that may arise from the use of this document or the information it contains. This document does not constitute an offer or invitation to acquire or subscribe shares, in accordance with the Spanish Securities Market Law of 1988 and its implementing regulations. Moreover, this document does not constitute an offer to purchase, sell or exchange securities, a solicitation of any offer to purchase, sell or exchange securities, a solicitation of any kind of voting rights, or approval in the United States of America or any other jurisdiction. Neither this document nor any part of it are of a contractual nature, and they cannot be used to form part or construe any agreement or any kind of undertaking. This presentation may contain information and statements or declarations with future projections regarding ROVI. The future projections do not constitute historical facts and are generally identifiable by the use of terms such as “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. In this regard, although ROVI believes that the expectations contained in such statements are reasonable, the investors and holders of ROVI shares are advised that the information and future projections are subject to risks and uncertainties, a large part of which are difficult to foresee, and which are, in general, out of ROVI’s control.
    [Show full text]